Staff Profile

Prof Jackson is a Consultant Haematologist at Newcastle Hospitals Trust, Newcastle upon Tyne and is a Professor of Haematology at Newcastle University.

He graduated from Cambridge and the Westminster School of Medicine. He gained his MRCP in 1986 and then moved to Newcastle University to undertake his MD, which he completed in 1992. Prof Jackson obtained his MRCPath in 1993, followed by his FRCP in 1999 and his FRCPath in 2000.

Throughout his career, Prof Jackson has received a number of awards, including special fellowship to the European School of Haematology and European Community Fellowship to the European School of Oncology. He has won the Van Bekkum medal at the EBMT and has been awarded the BSH gold medal.

He is a former president of the BSH and the BSBMT and served on the council of the RCPath. He has served on CTAAC and on the Blood wise clinical trials committee. He is a director of Myeloma UK and scientific secretary for the UKMF.

He leads the myeloma service at the University of Newcastle upon Tyne/Freeman hospital at the NCCC. He has been CI on the MRC Myeloma 9 and 11 and is currently the CI for myeloma 11 . He is part of the safety monitoring committee for all the MUK trials and previously as on the DMEC for the Endeavour and Clarion trials. His research interests focus on clinical trials and safety in the treatment of myeloma, development of long-term bone marrow transplant follow-up clinics, and the cytokine profile of acute and chronic graft-versus-host disease.

He has published over 200 peer reviewed papers as well as many book chapters and reviews.

• Tholouli E, Sturgess K, Dickinson RE, Gennery A, Cant AJ, Jackson G, Lordan J, Hambleton S, Slatter MA, Bigley V, Collin M. In vivo T-depleted reduced intensity transplantation for GATA2-related immune dysfunction. Blood 2018, 131(12), 1383-1387.
• Cytlak U, Resteu A, Bogaert D, Kuehn HS, Altmann T, Gennery A, Jackson G, Kumanovics A, Voelkerding KV, Prader S, Dullaers M, Reichenbach J, Hill H, Haerynck F, Rosenzweig SD, Collin M, Bigley V. Ikaros family zinc finger 1 regulates dendritic cell development and function in humans. Nature Communications 2018, 9, 1239.
• Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British Journal of Cancer 2017, 117(6), 835-839.
• Heaney JLJ, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA, Gregory WM, Cairns DA, Morgan G, Jackson G, Drayson MT. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. British Journal of Haematology 2017, 178(2), 220-230.
• Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang YW, Zheng TZ, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang ZM, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RCH, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJS, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager SL. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications 2017, 8, 14175.
• Law PJ, Sud A, Mitchell JS, Henrion M, Orlando G, Lenive O, Broderick P, Speedy HE, Johnson DC, Kaiser M, Weinhold N, Cooke R, Sunter NJ, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Carmichael J, Bailey JR, Pratt G, Rahman T, Pepper C, Fegan C, von Strandmann EP, Engert A, Försti A, Chen BW, da Silva MI, Thomsen H, Hoffmann P, Noethen MM, Eisele L, Jöckel KH, Allan JM, Swerdlow AJ, Goldschmidt H, Catovsky D, Morgan GJ, Hemminki K, Houlston RS. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific Reports 2017, 7, 41071.
• Green K, Pearce K, Sellar RS, Jardine L, Nicolson PL, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Peggs KS, Collin M. Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts. Biology of Blood and Marrow Transplantation 2017, 23(5), 805-812.
• Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood 2017, 130(14), 1639-1643.
• Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. The Lancet Haematology 2017, 4(12), e584-e594.
• Hyatt S, Jones RE, Heppel NH, Grimstead JW, Fegan C, Jackson GH, Hills R, Allan JM, Pratt G, Pepper C, Baird DM. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology 2017, 178(1), 94-98.
• Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 2017, 102(9), 1617-1625.
• Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 2017, 8(17), 27854-27867.
• Begum D, Ellis S, Price A, Smith C, Sherborne A, Proszek P, Johnson D, Walker B, Jones J, Pawlyn C, Jenner M, Drayson M, Owen R, Houlston R, Cairns D, Gregory W, Cook G, Davies F, Morgan G, Jackson G, Kaiser M. Deletion of CDKN2C drives the prognostic impact of deletion 1P in multiple myeloma. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Fondazione Ferrata Storti.
• Begum D, Ellis S, Smith C, Price A, Sherborne A, Proszek P, Johnson D, Walker B, Jones J, Pawlyn C, Jenner M, Drayson M, Owen R, Houlston R, Cairns D, Gregory W, Cook G, Davies F, Morgan G, Jackson G, Kaiser M. DYNAMIC EVOLUTION OF COPY NUMBER ABERRATIONS ACCOMPANIES DISEASE RELAPSE IN MULTIPLE MYELOMA. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Fondazione Ferrata Storti.
• Jones GL, Will A, Jackson GH, Webb NJ, Rule S. Evolving concepts in tumour lysis syndrome management - response to Ayed et al. British Journal of Haematology 2016, 173(3), 486-487.
• Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens OW, Forsti A, Nickel J, Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia 2016, 30(4), 883-888.
• Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen BW, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Joud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nothen MM, Rafnar T, Ross FM, da Silva MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature Communications 2016, 7, 12050.
• Johnson DC, Weinhold N, Mitchell JS, Chen BW, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Forsti A, Nickel J, Hoffmann P, Noethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nature Communications 2016, 7(10), 290.
• Pearce KF, Balavarca Y, Norden J, Jackson G, Holler E, Dressel R, Greinix H, Toubert A, Gluckman E, Hromadnikova I, Sedlacek P, Wolff D, Holtick U, Bickeboller H, Dickinson AM. Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia. International Journal of Immunogenetics 2016, 43(6), 404-412.
• de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica 2016, 101(2), E69-E71.
• de Tute RM, Rawstron AC, Cairns D, Pawlyn C, Davies F, Collett C, Jones J, Kaiser M, Chalmers A, Striha A, Cook G, Russell N, Drayson MT, Gregory WM, Jackson GH, Morgan GJ, Owen RG. Minimal residual disease predicts outcome in transplant ineligible myeloma patients: Results from the UK NCRI Myeloma XI trial. In: XXXVI World Congress of the International Society of Hematology. 2016, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Giles HV, Cook M, Richter A, Ferretti L, Kaiser M, Davies FE, Gregory WM, Owen RG, Jackson GH, Child JA, Morgan GJ, Drayson MT. Patients in the MRC Myeloma XI trial receiving induction chemotherapy for newly diagnosed multiple myeloma containing dexamethasone at full or moderated dose have significantly reduced half-life of IgG. In: XXXVI World Congress of the International Society of Hematology. 2016, Glasgow, UK: Wiley-Blackwell.
• Lee KC, Bramley RL, Cowell IG, Jackson GH, Austin CA. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II. Biochemical Pharmacology 2016, 103, 29-39.
• Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ, NCRI Haemato-Oncology CSG. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal 2016, 6, e506.
• Maggi M, Wu FCW, Jones TH, Jackson G, Behre HM, Hackett G, Martin-Morales A, Balercia G, Dobs AS, Arver STE, Maggio M, Cunningham GR, Isidori AM, Quinton R, Wheaton OA, Siami FS, Rosen RC, RHYME Investigators. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). International Journal of Clinical Practice 2016, 70(10), 843-852.
• Jones JR, Cairns D, Gregory W, Sigsworth R, Collett C, Pawlyn C, Striha A, Kaiser M, Drayson MT, Davies FE, Boyd K, Owen R, Morgan GJ, Jackson GH. The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option. In: XXXVI World Congress of the International Society of Hematology. 2016, Glasgow: Wiley-Blackwell.
• Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clinical Cancer Research 2016, 22(23), 5783-5794.
• Jardine L, Publicover A, Bigley V, Hale G, Pearce K, Dickinson A, Jackson G, Collin M. A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants. British Journal of Haematology 2015, 168(6), 874-881.
• Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Child JA, Davies FE, Walker BA, Morgan GJ. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes, Chromosomes and Cancer 2015, 54(2), 91-98.
• Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications 2015, 6, 6997.
• Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 2015, 125(5), 831-840.
• Sava GP, Speedy HE, Di Bernardo MC, Dyer MJS, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia 2015, 29(3), 748-751.
• Manville CM, Smith K, Sondka Z, Rance H, Cockell S, Cowell IG, Lee KC, Morris NJ, Padget K, Jackson GH, Austin CA. Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells. Biology Open 2015, 4(11), 1436-1447.
• Jones GL, Will A, Jackson GH, Webb NJA, Rule S, on Behalf of the British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. British Journal of Haematology 2015, 169(5), 661-671.
• Mitchell JS, Johnson DC, Litchfield K, Broderick P, Weinhold N, Davies FE, Gregory WA, Jackson GH, Kaiser M, Morgan GJ, Houlston RS. Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Scientific Reports 2015, 5, 12473.
• Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 2015, 125(12), 1932-1935.
• Kaiser MF, Boyle EM, Walker BA, Begum DB, Proszek P, Johnson DC, Pawlyn C, Jones JR, Savola S, Owen RG, Drayson MT, Cairns DA, Cook G, Gregory WM, Houlston RS, Davies FE, Jackson GH, Morgan GJ. Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Stein CK, Davies FE, Heuck C, Weinhold N, Chavan SS, Walker BA, Thanendrarajan S, Epstein J, Yaccoby S, Zangari M, van Rhee F, Kaiser MF, Jackson GH, Sonneveld P, Goldschmidt H, Bergsagel PL, Barlogie B, Morgan GJ. Molecular Subtyping and Risk Stratification for the Classification of Myeloma. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology 2015, 33(33), 3911-3920.
• Jones JR, Cairns DA, Sigsworth R, Collett C, Pawlyn C, Striha A, Melchor L, Kaiser MF, Drayson MT, Davies FE, Gregory WM, Boyd K, Owen RG, Jackson GH, Morgan GJ. Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Balavarca Y, Pearce KF, Norden J, Collin M, Jackson G, Holler E, Kolb HJ, Greinix H, Socie G, Toubert A, Rocha V, Gluckman E, Hromadnikova I, Sedlacek P, Wolff D, Holtick U, Dickinson AM, Bickeböller H. Predicting survival using clinical risk score and non-HLA immunogenetics. Bone Marrow Transplantation 2015, 50, 1445-1452.
• Pawlyn C, Davies FE, Cairns DA, Collett C, Chalmers A, Striha A, Jones JR, Garg M, Allotey D, Karunanithi K, Milligan D, Kaiser MF, Jenner MW, Cook G, Russell NH, Drayson MT, Owen RG, Gregory WM, Jackson GH, Morgan GJ. Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Melchor L, Jones JR, Lenive O, Peterson EA, Brioli A, Murison A, Wardell CP, Kaiser MF, Proszek P, Boyle EM, Begum DB, Pawlyn C, Johnson DC, Rapado I, Cairns DA, Gregory WM, Owen RG, Jackson GH, Drayson MT, Davies FE, Martinez-Lopez J, Houlston RS, Greaves M, Walker BA, Morgan GJ. Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Kaiser MF, Boyle EM, Walker BA, Begum DB, Proszek P, Johnson DC, Pawlyn C, Jones JR, Savola S, Owen RG, Drayson MT, Cairns DA, Cook G, Gregory WM, Houlston RS, Davies FE, Jackson GH, Morgan GJ. Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Baglin T, Carrington P, Jackson G, Board Trustees BSH. The British Society for Haematology: 'What have the Romans ever done for us?'. British Journal of Haematology 2015, 169(4), 605-607.
• Pawlyn C, Davies F, Cairns D, Collett C, Jones J, Kaiser M, Chalmers A, Striha A, Milligan D, Lindsay J, Chapman C, Allotey D, Shafeek S, Karunanithi K, Cook G, Russell N, Drayson M, Owen R, Gregory W, Jackson G, Morgan G. The Quadruplet Combination of Carfilzomib, Cyclophosphamide, Lenalidomide, and Dexamethasone is Safe and Well Tolerated as Induction Therapy for Newly Diagnosed, Transplant Eligible, Myeloma Patients. In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Fondazione Ferrata Storti.
• Pratt G, Bowcock S, Chantry A, Cook G, Jackson G, Lai M, Low E, Mulholland N, Owen R, Rabin N, Ramasamy K, Snowden JA, Streetly M, Wechalekar A, Yong K, Bird J. Time to redefine Myeloma. British Journal of Haematology 2015, 171(1), 1-10.
• Dharmagunawardena R, Pearce RM, Thomas G, Kirkland K, Perry J, Apperley JF, Medd P, Wilson KMO, Orchard K, Jackson G, Snowden JA, Cook G, Brown JS. A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function. Bone Marrow Transplantation 2014, 49(11), 1442-1443.
• Walker BA, Wardell CP, Murison A, Boyle EM, Melchor L, Pawlyn C, Kaiser MF, Begum D, Dahir N, Proszek P, Johnson DC, Qiang YW, Jones J, Cairns DA, Gregory W, Owen RG, Cook G, Drayson MT, Jackson G, Davies FE, Morgan GJ. Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Snowden JA, Ansari A, Sachchithanantham S, Jackson G, Thompson N, Lobo A, Sanderson J, Kazmi M. Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis. QJM: An International Journal of Medicine 2014, 107(11), 871-877.
• Kaiser MF, Murison A, Pawlyn C, Boyle EM, Johnson DC, Walker BA, Wu P, Begum D, Dahir N, Wardell CP, Proszek P, Cairns DA, Gregory W, Jackson G, Owen RG, Cook G, Drayson MT, Davies FE, Morgan GJ. High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Kaiser MF, Boyle EM, Walker BA, Pawlyn C, Begum D, Proszek P, Dahir N, Johnson DC, Savola S, Cairns DA, Gregory W, Jackson G, Owen RG, Cook G, Drayson MT, Davies FE, Morgan GJ. High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG. Minimal Residual Disease: What Are the Minimum Requirements? Reply. Journal of Clinical Oncology 2014, 32(5), 476-477.
• Boyle EM, Walker BA, Wardell CP, Murison A, Melchor L, Kaiser MF, Begum D, Proszek P, Dahir N, Johnson DC, Pawlyn C, Jones J, Mirabella F, Brioli A, Mikulasova A, Cairns DA, Gregory W, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Davies FE, Morgan GJ. Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Hurst EC, Conn J, Freeland S, Bailey A, Jackson G. Optimising the use of plerixafor in stem cell mobilisation. In: 54th Annual Scientific Meeting of the British Society for Haematology. 2014, Birmingham, UK: Wiley-Blackwell.
• Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Coy NN, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. British Journal of Haematology 2014, 166(1), 109-117.
• Horne B, Gilleece M, Jackson G, Snowden JA, Liebersbach S, Velikova G, Wright P. Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres. European Journal of Cancer Care 2014, 23(3), 349-362.
• Kaiser MF, Proszek P, Begum D, Dahir N, Walker BA, Savola S, Boyle EM, Johnson DC, Cairns DA, Gregory W, Jackson G, Owen RG, Cook G, Drayson MT, Davies FE, Morgan GJ. Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 2014, 123(22), 3414-3419.
• Laverick O, Publicover A, Jardine L, Green K, Potter A, Jackson GH, Collin M. Synergy of Unrelated Donor and Full Intensity Conditioning Breaks the Control of Graft Versus Host Disease By Alemtuzumab. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Melchor L, Murison A, Boyle EM, Wardell CP, Jones J, Kaiser MF, Pawlyn C, Johnson DC, Begum D, Proszek P, Dahir N, Cairns DA, Gregory W, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Walker BA, Morgan GJ. The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Pawlyn C, Kaiser MF, Walker BA, Wardell CP, Murison A, Johnson DC, Melchor L, Boyle EM, Jones J, Begum D, Dahir N, Proszek P, Cairns DA, Gregory W, Cook G, Owen RG, Drayson MT, Jackson G, Davies FE, Morgan GJ. The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
• Bird J, Tholouli E, Kyriakou C, Sati H, Ashcroft J, Owen R, Feyler S, Shafeek S, Hawkins S, Lynes J, Williams P, Rosettani B, Jackson G. The UK and Ireland Perspective: European Post-Approval Safety Study (Pass) in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Thalidomide. In: 19th Congress of the European Hematology Association. 2014, Milan, Italy: Ferrata-Storti Foundation.
• Brioli A, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leukemia & Lymphoma 2013, 54(9), 1975-1981.
• Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JAL, Neben K, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dorner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nature Genetics 2013, 45(10), 1221-1225.
• Green K, Sellar R, Jardine L, Ward J, Ferguson P, Nicolson P, Pearce K, Bigley V, Jackson G, Nagra S, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Collin MP, Peggs KS. Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study. In: 55th annual American Society of Hematology meeting. 2013, New Orleans, USA.
• Bacon CM, Wilkinson SJ, Spickett GP, Barge D, Lucraft HH, Jackson G, Rand V, Gennery AR. Epstein-Barr virus-independent diffuse large B-cell lymphoma in DNA ligase 4 deficiency. Journal of Allergy and Clinical Immunology 2013, 131(4), 1237-1239.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment. Clinical Cancer Research 2013, 19(21), 6030-6038.
• Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A, British Comm Stand Haematology, British Soc Blood Marrow Transplan, UK Virology Network. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. British Journal of Haematology 2013, 162(1), 25-39.
• Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG. Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Immunology 2013, 31(20), 2540-2547.
• Brioli A, Boyd KD, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. British Journal of Haematology 2013, 161(2), 291-294.
• Weinhold N, Johnson DC, Chubb D, Chen BW, Forsti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. The CCND1 c.870G > A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nature Genetics 2013, 45(5), 522-525.
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 2012, 119(1), 196-205.
• Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ, NCRI Haematology Oncology Studies. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012, 26(2), 349-355.
• McLornan DP, Mead AJ, Jackson G, Harrison CN. Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012. British Journal of Haematology 2012, 157(4), 413-425.
• Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet 2012, 379(9822), 1234-1244.
• Broderick P, Chubb D, Johnson DC, Weinhold N, Forsti A, Lloyd A, Olver B, Ma YP, Dobbins SE, Walker BA, Davies FE, Gregory WA, Child JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, Muhleisen TW, Nothen MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nature Genetics 2012, 44(1), 58-61.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Cook G, Feyler S, Johnson PRE, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, NCRI Haematological Oncology. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012, 97(3), 442-450.
• Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Shaw BE, Potter MN, British Comm Stand Haematology, British Comm Stand Haematology, British Soc Blood Marrow Transplan. Diagnosis and management of chronic graft-versus-host disease. British Journal of Haematology 2012, 158(1), 46-61.
• Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA, Natl Canc Res Inst. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012, 119(23), 5374-5383.
• Morgan GJ, Jackson GH, Davies F, Wu P, Gregory W, Bell SE, Szubert A, Coy NN, Drayson M, Owen RG, Feyler S, Ashcroft J, Ross F, Byrne J, Roddie H, Rudin C, Boyd K, Cook G, Child JA, Natl Canc Res Inst Haematological. Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. In: JOURNAL OF CLINICAL ONCOLOGY. 2012, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
• Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, Clark RE, Kazmi M, Abinun M, Jackson GH, Mackinnon S, Russell NH, Cook G, BSBMT Clinical Trials Comm. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. British Journal of Haematology 2012, 157(6), 742-746.
• Maggina P, Stroud C, Bourne H, Cole T, Collin M, Jackson G, Flood T, Barge D, Mansfield J, Hodges S, Spickett G, Gennery A. Idiopathic colitis following haematopoietic stem cell transplantation for chronic granulomatous disease: Three cases at a national centre. In: 15th Biennial Meeting European Society for Immunodeficiency (ESID). 2012, Florence, Italy: Springer.
• Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrcz-Krzemien S, Rocha V, Mohty M. Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 2012, 18(9), 1422-1429.
• Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk-Lesthuruge M, Rance HA, Padget K, Jackson GH, Adachi N, Austin CA. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity. Proceedings of the National Academy of Sciences 2012, 109(23), 8989-8994.
• Lee KC, Padget K, Curtis Hannah, Cowell IG, Moiani D, Sondka Z, Morris NK, Jackson GH, Cockell SJ, Tainer JA, Austin CA. MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA. Biology Open 2012, 1(9), 863-873.
• Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, Shaw BE, British Comm Stand Haematology, British Comm Stand Haematology, British Soc Blood Marrow Transplan. Organ-specific management and supportive care in chronic graft-versus-host disease. British Journal of Haematology 2012, 158(1), 62-78.
• Lane J, Slatter M, Nademi Z, Tierney P, Barge D, Hambleton S, Flood T, Cant A, Abinun M, Jackson G, Collin M, Gennery A. Outcome of haematopoietic stem cell transplantation in patients with chronic granulomatous disease at a national centre. In: 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). 2012, Geneva, Switzerland: Nature Publishing Group.
• Sturgess K, Slatter M, Bigley V, Dickinson R, Haniffa M, McGovern N, Jardine L, Jackson G, Cant A, Gennery A, Hambleton S, Collin M. Reduced-intensity haematopoietic stem cell transplant rescues immune function and corrects pulmonary alveolar proteinosis in DCML deficiency/GATA 2 mutation. In: 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT). 2012, Geneva, Switzerland: Nature Publishing Group.
• Pawlyn C, Davies FE, Gregory WM, Szubert AJ, Bell SE, Ouzman J, Drayson MT, Owen RG, Jackson GH, Russell NH, Morgan GJ. Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Protheroe RE, Kirkland KE, Pearce RM, Kaminaris K, Bloor A, Potter MN, Nagra S, Gilleece MH, McQuaker IG, Jackson G, Cook G, Marks DI. The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study. BONE MARROW TRANSPLANTATION 2012, 47(1), 88-94.
• Brioli A, Ross FM, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen RG, Jackson GH, Cavo M, Davies FE, Morgan GJ. The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J, Ross FM, Jackson GH, Child AJ, Davies FE, Morgan GJ. A Gene Expression-Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment. Clinical Cancer Research 2011, 17(19), 6347-6355.
• de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JAE. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leukemia Research 2011, 35(9), 1233-1240.
• Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Coy NN, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA, NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011, 118(5), 1231-1238.
• Bigley V, Haniffa M, Doulatov S, Wang XN, Dickinson R, McGovern N, Spence L, Pagan S, Carey C, Dimmick I, Chua I, Wallis J, Lordan J, Morgan C, Kumararatne DS, Doffinger R, van der Burg M, van Dongen J, Cant A, Jackson G, Dick JE, Hambleton S, Collin M. Dendritic cell, monocyte, B and NK lymphoid deficiency: a novel but potentially fatal haematological disorder curable with haematopoietic stem cell transplantation. In: Bone Marrow Transplantation: 37th European Group for Bone and Marrow Transplantation. 2011, Paris, France: Nature Publishing Group.
• Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, Natl Canc Res Inst. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncology 2011, 12(8), 743-752.
• Cooles FAH, Jackson GH, Menon G, Isaacs JD. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology 2011, 50(4), 810-812.
• Tapper W, Chiecchio L, Dagrada GP, Konn ZJ, Stockley DM, Szubert AJ, Gregory WM, Bell SE, Jackson GH, Child JA, Morgan GJ, Ross FM. Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma. Journal of Clinical Oncology 2011, 29(2), E37-E39.
• Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ, NCRI Haematology Oncology Studies Group. Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. Clinical Cancer Research 2011, 17(24), 7776-7784.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA. MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Shamim Z, Ryder LP, Christensen IJ, Toubert A, Norden J, Collin M, Jackson G, Dickinson AM, Muller K. Prognostic Significance of Interleukin-7 Receptor-alpha Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A Confirmatory Study. Transplantation 2011, 91(7), 731-736.
• Sturgess K, Slatter M, Bigley V, Haniffa M, Wang XN, Dickinson R, McGovern N, Jardine L, Pagan S, Chua I, Wallis J, Lordan J, Morgan C, Cant A, Gennery A, Edmondson R, Bacon C, Black F, Kirkham N, Jackson GH, Hambleton S, Collin MP. Reduced Intensity Hematopoietic Stem Cell Transplant Rescues Immune Function and Corrects Pulmonary Alveolar Proteinosis in DCML Deficiency/GATA 2 Mutation. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Boyd KD, Ross FM, Drayson MT, Owen RG, Szubert AJ, Gregory WM, Wardell CP, Davies FE, Jackson GH, Child JA, Morgan GJ. The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Ruffin N, Ahmed SS, Osorio LM, Wang XN, Jackson GH, Collin MP, Ekre HP, Chiodi F, Dickinson AM. The Involvement of Epithelial Fas in a Human Model of Graft Versus Host Disease. Transplantation 2011, 91(9), 946-951.
• Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R, Littlewood T, Jackson G, Milpied N, Boogaerts M, Hunter A, Janssen JJWM, Montoto S, Sureda A. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia 2011, 25(3), 551-555.
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. In: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, FL: Blood: American Society of Hematology.
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Pratt G, Fenton JAL, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JAE, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. British Journal of Haematology 2010, 150(3), 371-373.
• Dickinson A, Pearce K, Jackson G, Collin M, Norden J, Holler E, Greinix H, Bickeboller H, Balvarca Y, Rocha V, Kolb H, Hromadnikova I, Sedlacek P, Gratwohl A. Clinical and genetic risk assessment for overall survival in haematopoietic stem cell transplantation. In: 36th Annual Meeting of the European Group for Blood and Marrow Transplantat/9th Meeting of the EBMT Data Management Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Quality Management Meeting. 2010, Vienna, Austria: Bone Marrow Transplantation, Nature Publishing Group.
• Morgan G, Davies F, Gregory W, Bell SE, Szubert A, Coy NN, Drayson M, Owen RG, Jackson GH, Child JA. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study. In: JOURNAL OF CLINICAL ONCOLOGY. 2010, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
• Matthey F, Parker A, Rule SAJ, Wimperis JZ, Ardeshna KM, Bird JM, Cullis J, Lyttelton MPA, McMillan A, Jackson GH. Facilities for the treatment of adults with haematological malignancies - 'Levels of Care': BCSH Haemato-Oncology Task Force 2009. HEMATOLOGY 2010, 15(2), 63-69.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Drayson MT, Ashcroft J, Owen RG, Cook G, Ross FM, Jackson GH, Russell NH, Child JA. Optimising Bone Disease In Myeloma, Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints Results of the MRC Myeloma IX Trial. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Drayson MT, Owen RG, Cook G, Ross FM, Jackson GH, Child JA. Thalidomide Maintenance Significantly Improves Progression Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used MRC Myeloma IX Results. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Crowther M, Avenell A, Jackson GH, Paneesha S, Culligan DJ. Weight loss is still a problem with reduced intensity conditioning transplants and modern supportive care. In: BRITISH JOURNAL OF HAEMATOLOGY. 2010, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA: WILEY-BLACKWELL.
• Guest JF, Smith H, Sladkevicius E, Jackson G. Cost-Effectiveness of Pentostatin Compared With Cladribine in the Management of Hairy Cell Leukemia in the United Kingdom. CLINICAL THERAPEUTICS 2009, 31, 2398-2415.
• Owen RG, Rawstron AC, Drayson MT, Davies FE, Jackson GH, Ross FM, Gregory WM, Szubert AJ, Bell SE, Navarro-Coy N, Heatley F, Morgan GJ, Child AJ. MRD Studies in MM: Data from the MRC Myeloma IX Trial. In: CLINICAL LYMPHOMA & MYELOMA. 2009, 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA: CIG MEDIA GROUP, LP.
• Al-Bermani A, Figueiredo F, Speight EL, Jackson GH, Pandit R. Necrobiotic xanthogranuloma masquerading as posterior scleritis. EYE 2009, 23(1), 239-240.
• Drayson MT, Morgan GJ, Jackson GH, Davies FE, Owen RG, Rosss FM, Gregory WM, Navarro-Coy N, Heatley F, Bell SE, Szubert AJ, Child JA. Prospective Study of Serum FLC and Other M-Protein Assays: When and How to Measure Response?. In: CLINICAL LYMPHOMA & MYELOMA. 2009, 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA: CIG MEDIA GROUP, LP.
• Bhavnani M, Braithwaite J, Burthem J, Crotty G, Gibson B, Hutchinson C, Jackson GH, Layton M, Lucas G, Macartney C, Matthey F, Pardoe L, Radia D, Webb S. British Society for Haematology, slide session, Annual Scientific Meeting, Bournemouth, 2007. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 2008, 30(2), 95-104.
• Morgan GJ, Davies FE, Cavenagh JD, Jackson GH. Position statement on the use of bortezomib in multiple myeloma. International Journal of Laboratory Hematology 2008, 30(1), 1-10.
• Morgan GJ, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K, Gregory W, Jackson G, Drayson MT, Jenner MW, Child JA. Thalidomide combinations improve response rates; Results from the MRC IX study. In: BLOOD. 2007, 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA: AMER SOC HEMATOLOGY.
• Maertens P, Jackson G, Glasmacher A, Landwehr J. Renal safety monitoring with the use of bisphosphonates: European market research results. In: ANNALS OF ONCOLOGY. 2004, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS.
• Leung E, Shenton BK, Green K, Gould K, Jackson G, Talbot D. Changes in EBV gene load in renal transplant recipients. Transplantation Proceedings 2003, 35(2), 794-795.
• Middleton PG, Dickinson AM, Jarvis M, Cavet J, Cullup H, Jackson GH. Clinical and genotypic risk factors for GvHD are modulated by prophylaxis: A multicentre cohort study of HLA matched sib-allo BMT. In: Genes and Immunity: 17th European Histocompatability Conference. 2003, Baden, Germany: Nature Publishing Group.
• Jackson G, Richardson C, Morgan G, Smith G, Johnson P, Davies J, Burnett A, Poynton C, Wilson K, Wareham E, Stars A, Tollerfield S. Fludarabine phosphete and melphalan - An immunosuppressive reduced intensity conditioning (RIC) regimen for allogeneic stem cell transplantation in patients with a range of hematological malignancies. In: 7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION. 2002, VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY: MEDIMOND S R L.
• Wang XN, Lange C, Schulz U, Sviland L, Eissner G, Oliver KM, Jackson GH, Holler E, Dickinson AM. Interleukin-10 modulation of alloreactivity and graft-versus-host reactions. Transplantation 2002, 74(6), 772-778.
• Jarvis M, Schulz U, Dickinson AM, Sviland L, Jackson G, Konur A, Wang XN, Hromadnikova I, Kolb HJ, Eissner G, Holler E. The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions. Journal of Clinical Pathology 2002, 55(2), 127-132.
• Leung E, Shenton BK, Jackson G, Gould FK, Yap C, Talbot D. Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood. Journal of Immunological Methods 2002, 270(2), 259-267.
• Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, Mackie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. British Journal of Haematology 2001, 112(1), 127-137.
• Robertson JD, Testa NG, Russell NH, Jackson G, Parker AN, Milligan DW, Stainer C, Chakrabarti S, Dougal M, Chopra R. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplantation 2001, 27(12), 1283-1286.
• Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR. Erythroleukaemia in the north of England: a population based study. Journal of Clinical Pathology 2001, 54(8), 608-612.
• Sviland L, Hromadnikova I, Sedlacek P, Cermakova M, Stechova K, Holler E, Eissner G, Schulz U, Kolb HJ, Jackson G, Wang XN, Dickinson AM. Histological correlation between different centers using the skin explant model to predict graft-versus-host disease following bone marrow transplantation. Human Immunology 2001, 62(11), 1277-1281.
• Cavet J, Dickinson AM, Norden J, Taylor PRA, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98(5), 1594-1600.
• Wang XN, Dickinson AM, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TNM, Haanen JBAG, Mutis T, Goulmy E. Minor histocompatibility antigen specific CTLs and in situ skin graft versus host reactions. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2001, Orlando, Florida, USA: American Society of Hematology.
• Gerstenkorn C, Jackson G, Di Franco F, Thomusch O, Talbot D. Outcome of PTLD in renal and liver allograft recipients. Transplantation Proceedings 2001, 33(4), 2469-2472.
• Adams I, Taylor PRA, Jackson GH, Angus B, Watson P, Mounter P, McKay P, Dickinson AM, Oliver K, Jack F. Development of a novel prognostic score for mantle cell lymphoma. In: BLOOD. 2000.
• Holler E, Schulz U, Jarvis M, Dickinson AM, Sviland L, Hromadnikova I, Jackson G, Konur A, Eissner G, Andreesen R. The detection of keratinocyte apoptosis in a human skin explant assays for prediction of graft-versus-host disease. In: BLOOD. 2000.
• Rutter MR, McComb JM, Kesteven P, Marshall SM, Jackson G. Endothelial dysfunction, disordered coagulation and fibrinolysis in patients with type 2 diabetes and microalbuminuria. In: Forty-first Annual Meeting of the American Society of Hematology. 1999, Oakland, California, USA: American Society of Hematology.
• Moorthy IT, Chippindale AJ, Jackson GH, McCluskey S. Grey-scale ultrasound appearances of chronic parotid enlargement in anorexia nervosa. CLINICAL RADIOLOGY 1998, 53(8), 623-623.
• Taylor P, Jackson G, Lucraft H, White J, Angus B, Proctor S. A novel treatment for Hodgkin's disease in the elderly: P.COME. In: BLOOD. 1997, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399: W B SAUNDERS CO.
• Chinnery PF, Shaw PJ, Ince PG, Jackson GH, Bishop RI. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome [15]. Journal of Neurology Neurosurgery and Psychiatry 1997, 62(3), 300-301.
• JACKSON GH, CAREY PJ, CANT AJ, BOWN NP, REID MM. MYELODYSPLASTIC SYNDROMES IN CHILDREN. BRITISH JOURNAL OF HAEMATOLOGY 1993, 84(1), 185-186.
• PROCTOR SJ, JACKSON GH, LENNARD AL, MARKS J. LYMPHOMATOID PAPULOSIS - RESPONSE TO TREATMENT WITH RECOMBINANT INTERFERON ALFA-2B. JOURNAL OF CLINICAL ONCOLOGY 1992, 10(1), 170-170.
• JACKSON GH, NOBLE RS, MAUNG ZT, MAIN J, SMITH SR, REID MM. SEVERE HEMOLYSIS AND RENAL-FAILURE IN A PATIENT WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA. JOURNAL OF CLINICAL PATHOLOGY 1992, 45(2), 176-177.
• Heaney JLJ, Campbell JP, Iqbal G, Cairns D, Richter A, Child JA, Gregory W, Jackson G, Kaiser M, Owen R, Davies F, Morgan G, Dunn J, Drayson MT. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia 2018, 32, 1727-1738.
• Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018, 2(10), 1157-1169.
• Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos M-V, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Blade J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018, 32(7), 1542-1560.